-
Media ReleaseRAD001 Combined with Sandostatin LAR® Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
-
Media ReleaseRAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
-
Media ReleaseNovartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
-
Media ReleaseVideo: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
-
Media ReleaseEarly Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
-
Media ReleaseVideo: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
-
Media ReleaseRAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media ReleaseStrength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
-
Media ReleaseVIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
-
Media ReleaseEverolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
-
Media ReleaseVideo and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
-
Media ReleasePhoto: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment